Pazopanib for the treatment of breast cancer

Expert Opinion on Investigational Drugs

Volumn 21, Issue 2, 2012, Pages 217-225

  Amiri Kordestani, Laleh ^a   Tan, Antoinette R ^b   Swain, Sandra M ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^c WASHINGTON CANCER INSTITUTE   (United States)

Author keywords

Breast cancer; Pazopanib; PDGFR; Tyrosine kinase inhibitor; VEGF; VEGFR

Indexed keywords

ADENOSINE TRIPHOSPHATE; AFLIBERCEPT; ANASTROZOLE; AXITINIB; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CEDIRANIB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EXEMESTANE; IXABEPILONE; LAPATINIB; MOTESANIB; NAVELBINE; PACLITAXEL; PAZOPANIB; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PTC 299; RABEPRAZOLE; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VATALANIB;

ABSCESS; ADVANCED CANCER; ANASTOMOSIS DEHISCENCE; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTERY THROMBOSIS; ARTICLE; ASTHENIA; BLEEDING; BRAIN METASTASIS; BREAST CANCER; CANCER INHIBITION; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; ESOPHAGUS CANCER; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GASTROINTESTINAL HEMORRHAGE; HAIR COLOR; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPOCALCEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOPIGMENTATION; HYPOTHYROIDISM; INFECTION; KIDNEY CARCINOMA; LEUKOPENIA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; OVARY CANCER; PNEUMONIA; PROGRESSION FREE SURVIVAL; PROTEINURIA; QT PROLONGATION; RECOMMENDED DRUG DOSE; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; TORSADE DES POINTES; TREATMENT RESPONSE;

ANGIOGENESIS INHIBITORS; BREAST NEOPLASMS; FEMALE; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; SULFONAMIDES; TUMOR MARKERS, BIOLOGICAL;

EID: 84855802138     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.652304     Document Type: Article

References (85)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212-36
2. Chia SK, Speers CH, D'Yachkova Y, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 2007;110:973-9 (Pubitemid 47312861)
3. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989;339:58-61 (Pubitemid 19115892)
4. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992;84:1875-87 (Pubitemid 23004615)
5. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8
6. Yoshiji H, Gomez DE, Shibuya M, Thorgeirsson UP. Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res 1996;56:2013-16 (Pubitemid 26119899)
7. Relf M, LeJeune S, Scott PA, et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997;57:963-9 (Pubitemid 27098025)
8. Linderholm B, Grankvist K, Wilking N, et al. Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. J Clin Oncol 2000;18:1423-31 (Pubitemid 30205387)
9. Linderholm B, Tavelin B, Grankvist K, Henriksson R. Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. J Clin Oncol 1998;16:3121-8 (Pubitemid 28417435)
10. Gasparini G, Toi M, Gion M, et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 1997;89:139-47 (Pubitemid 27034790)
11. Toi M, Inada K, Suzuki H, Tominaga T. Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res Treat 1995;36:193-204
12. Eppenberger U, Kueng W, Schlaeppi JM, et al. Markers of tumor angiogenesis and proteolysis independently define high-and low-risk subsets of node-negative breast cancer patients. J Clin Oncol 1998;16:3129-36 (Pubitemid 28417436)
13. Manders P, Beex LV, Tjan-Heijnen VC, et al. The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy. Br J Cancer 2002;87:772-8 (Pubitemid 35178755)
14. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;358:2039-49 (Pubitemid 351656458)
15. Price DJ, Miralem T, Jiang S, et al. Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. Cell Growth Differ 2001;12:129-35 (Pubitemid 32677998)
16. Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006;24:769-77 (Pubitemid 46622044)
17. Kranz A, Mattfeldt T, Waltenberger J. Molecular mediators of tumor angiogenesis: enhanced expression and activation of vascular endothelial growth factor receptor KDR in primary breast cancer. Int J Cancer 1999;84:293-8 (Pubitemid 29256757)
18. Nakopoulou L, Stefanaki K, Panayotopoulou E, et al. Expression of the vascular endothelial growth factor receptor-2/Flk-1 in breast carcinomas: correlation with proliferation. Hum Pathol 2002;33:863-70
19. Bronzert DA, Pantazis P, Antoniades HN, et al. Synthesis and secretion of platelet-derived growth factor by human breast cancer cell lines. Proc Natl Acad Sci USA 1987;84:5763-7 (Pubitemid 17130415)
20. Ginsburg E, Vonderhaar BK. Stimulation of growth of human breast cancer cells (T47D) by platelet derived growth factor. Cancer Lett 1991;58:137-44
21. Carvalho S, e Silva AO, Milanezi F, et al. c-KIT and PDGFRA in breast phyllodes tumours: overexpression without mutations? J Clin Pathol 2004;57:1075-9 (Pubitemid 39331359)
22. Bhardwaj B, Klassen J, Cossette N, et al. Localization of platelet-derived growth factor beta receptor expression in the periepithelial stroma of human breast carcinoma. Clin Cancer Res 1996;2:773-82 (Pubitemid 26135343)
23. de Jong JS, van Diest PJ, van der Valk P, Baak JP. Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis. J Pathol 1998;184:53-7 (Pubitemid 28086153)
24. Ariad S, Seymour L, Bezwoda WR. Platelet-derived growth factor (PDGF) in plasma of breast cancer patients: correlation with stage and rate of progression. Breast Cancer Res Treat 1991;20:11-17
25. Seymour L, Dajee D, Bezwoda WR. Tissue platelet derived-growth factor (PDGF) predicts for shortened survival and treatment failure in advanced breast cancer. Breast Cancer Res Treat 1993;26:247-52 (Pubitemid 23304240)
26. Seymour L, Bezwoda WR. Positive immunostaining for platelet derived growth factor (PDGF) is an adverse prognostic factor in patients with advanced breast cancer. Breast Cancer Res Treat 1994;32:229-33 (Pubitemid 24313348)
27. Paulsson J, Sjoblom T, Micke P, et al. Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am J Pathol 2009;175:334-41
28. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90
29. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34 (Pubitemid 46089673)
30. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24 (Pubitemid 46089672)
31. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329-38 (Pubitemid 44528723)
32. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364:501-13
33. Wells SA, Robinson BG, Gagel RF, et al. Vandetanib in locally advanced or metastatic medullary thyroid cancer : a randomized, double-blind phase III trial (ZETA). J Clin Oncol 2010;28(Suppl):abstract 5503
34. Harris PA, Boloor A, Cheung M, et al. Discovery of 5-[[4-[(2,3-dimethyl- 2Hindazol-6-yl)methylamino]-2-pyrimidinyl] amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J Med Chem 2008;51:4632-40
35. Gotink KJ, Verheul HM. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis 2010;13:1-14
36. Kumar R, Knick VB, Rudolph SK, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007;6:2012-21 (Pubitemid 47052491)
37. Gril B, Palmieri D, Qian Y, et al. Pazopanib reveals a role for tumor cell B-Raf in the prevention of HER2+ breast cancer brain metastasis. Clin Cancer Res 2011;17:142-53
38. Hurwitz HI, Dowlati A, Saini S, et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 2009;15:4220-7
39. Heath EI, Forman K, Malburg L, et al. A phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid tumors. Invest New Drugs 2011 [Epub ahead of print]
40. Heath EI, Chiorean EG, Sweeney CJ, et al. A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors. Clin Pharmacol Ther 2010;88:818-23
41. Goh BC, Reddy NJ, Dandamudi UB, et al. An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumors. Clin Pharmacol Ther 2010;88:652-9
42. Xu CF, Reck BH, Xue Z, et al. Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism. Br J Cancer 2010;102:1371-7
43. Pazopanib FDA drug label
44. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28:1061-8
45. Tan AR, Dowlati A, Jones SF, et al. Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors. Oncologist 2010;15:1253-61
46. Burris HA III, duBois A, Dowlati A, et al. Pazopanib combination with paclitaxel and carboplatin in patients with advanced solid tumors and gynecological cancers: results of two phase I studies. Mol Targets Cancer Ther 2009;8(12):Supplement 1(abstract A6)
47. Study of pazopanib, paclitaxel, and carboplatin in patients with advanced solid tumors (NCT01407562). Available from: http://clinicaltrials.gov/ct2/show/ NCT01407562? term=NCT01407562&rank=1
48. Available from: http://clinicaltrials.gov
49. Dejonge M, Savage S, Verweij J, et al. A phase I, open-label study of the safety and pharmacokinetics (PK) of pazopanib (P) and lapatinib (L) administered concurrently. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006;24:18 Suppl 20
50. A phase I, open-label, study of pazopanib in combination with epirubicin or doxorubicin for advanced solid tumors (NCT00722293). Available from: http://clinicaltrials.gov/ct2/show/NCT00722293? term=NCT00722293&rank=1
51. Fasolo A, Sessa C, Bauer JA, et al. Phase Ib clinical and pharmacological study of multiple schedules of pazopanib (P) and epirubicin (EPI) in patients with advanced solid tumors. J Clin Oncol 2010;28(Suppl):abstract 3047
52. Taylor SK, Chia S, Dent S, et al. A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium. Oncologist 2010;15:810-18
53. Slamon D, Gomez H, Kabbinavar F, et al. Phase 2 study of dual VEGF/HER2 blockade with pazopanib + lapatinib in patients with first-line HER2 positive advanced or metastatic (adv/met) breast cance. J Clin Oncol 2008;26(20 Suppl):abstract 1016
54. Slamon D, Stemmer SM, Johnston S, et al. Phase 2 study of dual VEGF/HER2 blockade with pazopanib + lapatinib in patients with first-line HER2 positive advanced or metastatic (adv/met) breast cancer [abstract 4114]. San Antonio: 2008
55. Rastogi P, Buyse ME, Tan AR, et al. A phase II clinical trial of four cycles of doxorubicin and cyclophosphamide followed by weekly paclitaxel given concurrently with pazopanib as neoadjuvant therapy followed by postoperative pazopanib for women with locally advanced breast cancer (LABC): A phase II trial of the NSABP Foundation Research Group (FB-6/VEG110264). J Clin Oncol 2010;28(Suppl):abstract TPS107
56. Miller K, Brown C, Perkins S, et al. A pilot study of vascular endothelial growth factor inhibition with pazopanib in patients (pts) with lymphedema following breast cancer treatment [abstract P2-14-02]. San Antonio: 2010
57. Van der Auwera I, Van Laere SJ, Van den Eynden GG, et al. Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. Clin Cancer Res 2004;10:7965-71 (Pubitemid 39587537)
58. Kaufman B, Trudeau M, Awada A, et al. Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study. Lancet Oncol 2009;10:581-8
59. Study of Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer (NCT00558103). Available from: http://clinicaltrials.gov/ct2/show/NCT00558103?term=lapatinib +pazopanib+breast&phase=2&rank=1
60. Eveno C, le Maignan C, Soyer P, et al. Late anastomotic colonic dehiscence due to antiangiogenic treatment, a specific drug-class complication requiring specific treatment: an example of pazopanib complication. Clin Res Hepatol Gastroenterol 2011;35:135-9
61. Kapadia S, Hapani S, Wu S. Risk of high-grade liver toxicity with pazopanib in patients with cancer: a meta-analysis. J Clin Oncol 2011;29 (suppl; abstr 4595)
62. Xu C, Reck BH, Goodman VL, et al. Association of the hemochromatosis (HFE) gene with pazopanib-induced transaminase elevations in renal cell carcinoma. J Clin Oncol 2010;28(Suppl):abstract 3019
63. Routhouska S, Gilliam AC, Mirmirani P. Hair depigmentation during chemotherapy with a class III/V receptor tyrosine kinase inhibitor. Arch Dermatol 2006;142:1477-9 (Pubitemid 44790642)
64. Sideras K, Menefee ME, Burton JK, et al. Effect of pazopanib on hair and skin hypopigmentation: a series of three patients. J Clin Oncol 2010;28(Suppl):abstract e13602
65. Balagula Y, Wu S, Su X, et al. The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis. Invest New Drugs 2011 [Epub ahead of print]
66. Xu CF, Bing NX, Ball HA, et al. Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes. J Clin Oncol 2011;29:2557-64
67. Nikolinakos PG, Altorki N, Yankelevitz D, et al. Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib. Cancer Res 2010;70:2171-9
68. Baruchel S, Wu B, Mokhtari RB, et al. Surrogate biomarkers of antiangiogenesis in Children's Oncology Group (COG) phase I trials. J Clin Oncol 2011;29:(suppl; abstr 9502)
69. Burstein HJ, Elias AD, Rugo HS, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008;26:1810-16
70. Bianchi G, Loibl S, Zamagni C, et al. Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anticancer Drugs 2009;20:616-24
71. Baselga J. 15th Congress of the European CanCer Organization (ECCO 15) and the 34th European Society for Medical Oncology (34th ESMO) Multidisciplinary Congress; 23 September 2009; abstract 3LBA
72. Kozloff M, Chuang E, Starr A, et al. An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer. Ann Oncol 2010;21:1436-41
73. Available from: http://clinicaltrials.gov/ct2/show/NCT01060514? term=NCT01060514&rank=1
74. Available from: http://clinicaltrials.gov/ct2/show/NCT01012362? term=NCT01012362&rank=1
75. Available from: http://clinicaltrials.gov/ct2/show/NCT00722293? term=NCT00722293&rank=1
76. Available from: http://clinicaltrials.gov/ct2/show/NCT01165385? term=NCT01165385&rank=1
77. Available from: http://clinicaltrials.gov/ct2/show/NCT00060151? term=NCT00060151&rank=1
78. Available from: http://clinicaltrials.gov/ct2/show/NCT00388076? term=NCT00388076&rank=1
79. Available from: http://clinicaltrials.gov/ct2/show/NCT01407562? term=NCT01407562&rank=1
80. Available from: http://clinicaltrials.gov/ct2/show/NCT00158782? term=NCT00158782&rank=1
81. Available from: http://clinicaltrials.gov/ct2/show/NCT01394211? term=NCT01394211&rank=1
82. Available from: http://clinicaltrials.gov/ct2/show/NCT00509587? term=NCT00509587&rank=1
83. Available from: http://clinicaltrials.gov/ct2/show/NCT00347919? term=NCT00347919&rank=1
84. Available from: http://clinicaltrials.gov/ct2/show/NCT00615524? term=NCT00615524&rank=1
85. Available from: http://clinicaltrials.gov/ct2/show/NCT00849472? term=NCT00849472&rank=1